Have you visited our website recently?
If so, you’ve seen some significant changes in the look of our site.
Since our company’s inception over 5 years ago, our mission has been to find biological solutions for important neurological health issues. At first, this stemmed from our Founder and CEO Rich Uhlig’s desire to have better diagnostic and treatment tools for concussion, after his son experienced a severe head injury playing youth hockey.
Since then, Quadrant has grown considerably as a result of our game changing epigenetic research. But the goal has remained the same- translating use this research to help our community.
So why the change?
In light of our growth as a world leader in epigenetic diagnostics for neurological disorders, we thought it important to refresh the Quadrant brand to appropriately reflect this rapid growth and evolution.
Speaking of latest news…
Thanks to collaborations with institutions such as SUNY Upstate Medical University and Penn State College of Medicine, we have plans to introduce a whole line of Clarifi tests with the goal to accurately identify Parkinson’s disease, Traumatic Brain Injuries (TBI), and Anorexia using epigenetic research that’s similar to the science behind Clarifi ASD.
And we’re happy to share we’re not the only ones excited by our research!
Just last month, our Parkinson’s disease research in collaboration with Frank Middleton PhD, Dragos Mihalia MD, and Susan Baser MD, was honored at the International Congress of Parkinson’s Disease and Movement Disorders in Nice, France.
Check out some of our team members:
Be sure to stay tuned with our latest research and news related to our autism saliva test, ClarifiASD.